Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
about
Current status of PET imaging in Huntington's diseaseTreatment of Huntington's disease.Shaping the role of mitochondria in the pathogenesis of Huntington's diseaseMolecular Imaging Markers to Track Huntington’s Disease PathologyNeuroimaging in Huntington's disease.T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression.Neuroimaging and therapeutics in movement disorders.Molecular Imaging of Huntington's Disease.Seeking brain biomarkers for preventive therapy in Huntington disease.Pathophysiology of chorea and bradykinesia in Huntington's disease.Motor-Language Coupling in Huntington's Disease Families.Functional neuroimaging and chorea: a systematic review.Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.Transplantation of induced pluripotent stem cells improves functional recovery in Huntington's disease rat model.Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders.Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease.Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant miceComponents of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.Selective defect of in vivo glycolysis in early Huntington's disease striatumThe paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.Positron emission tomography imaging of transplant function.Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.Monitoring Huntington's disease progression through preclinical and early stagesMetabolic disruption identified in the Huntington's disease transgenic sheep model.Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.Elevated arteriolar cerebral blood volume in prodromal Huntington's disease.Early Detection of Huntington Disease.Circadian dysfunction in response to in vivo treatment with the mitochondrial toxin 3-nitropropionic acid.PET/CT in diagnosis of movement disorders.Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington's disease patients.Prospects for neuroprotective therapies in prodromal Huntington's disease.PET Imaging in Huntington's Disease.Protein regulation of induced pluripotent stem cells by transplanting in a Huntington's animal model.Basal Ganglia dysfunctions in movement disorders: What can be learned from computational simulations.Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease.Triheptanoin for the treatment of brain energy deficit: A 14-year experience.Nucleic Acid-Based Therapy Approaches for Huntington's Disease
P2860
Q26768644-DDD0706E-0738-4DE9-B1BE-B4D900C37458Q26782004-D4C9AF38-C2ED-4CA5-A75A-3918B7FC7A75Q28384036-310F79E7-F176-4C0B-AE98-3EC5DF1D4FA8Q29248766-10D9EC1D-937A-4B56-89ED-18B6DD774FAEQ30834004-DD43278E-3A61-4B08-A386-141475C27786Q30919084-070B9E75-1493-497E-9A63-8988BA6093D1Q30989947-20173D21-1088-4321-963A-A216C2E0B8E5Q31139686-86709138-AD8C-461C-A019-224021904856Q33606063-6667C8C2-0036-4793-B48C-F60F1FC0FDAEQ33647085-FB13602C-C563-4708-89C7-6A3B80FEB143Q33743709-6D61B1E6-97E5-43CA-87B8-ABF91C4F5438Q33820298-09AC00AD-36B0-43A9-9B10-27F9AC7EC978Q33831774-973D17B6-6856-4E2A-8603-286B296D3562Q33939904-04BB78B6-035A-4914-91CC-857AD92E87E5Q34105520-7AA5D340-26D6-4E15-9217-354C512006F4Q34153434-481D1005-5F9C-4A87-BDBA-025E63D1406DQ34273178-E0812912-96EC-47FF-B2B4-1F33EB40885EQ34809057-DDF630FE-CA24-46F5-B181-6735BC6BE176Q35049600-0E4F2EE0-5654-4EB4-A534-CF71FBF183DCQ35634060-83659E31-48C3-4C42-8207-0D54C2C9ED79Q36045254-AB821A17-362D-4DA5-B2F2-4769C5CA35B4Q36045301-16CCD10D-D9DD-4896-AB5A-815CD683BA74Q36045402-134A6C39-92B3-4DBC-8330-37F52EAF64EFQ36100251-564BE150-3129-43F9-AABC-977BAE0616D5Q36129732-11CA351B-C1F7-4BFD-A0AE-3490E23712E9Q36459201-683125EF-6704-4CE5-BB36-5F5D76D31C98Q36569413-8FD62B7E-F04D-4146-9CDF-6009855F15C5Q37106123-E65B88A5-04EB-4551-8D59-4A7F6246FC99Q37325474-26AC53C2-46B4-4D12-A520-DD43707F5913Q37386063-87EE1FAC-5DE5-4CC3-89F2-234857344C62Q37476957-7A7F14D8-9368-4B51-9430-36E7D57EE57EQ37896142-C094CD0E-BD3E-4184-BBDA-610DA0B7BFCFQ37980384-2C7834F6-5A4D-4186-8DEB-DDC8E6F0B6D7Q38191477-AAEC0C70-C0E1-423B-A784-3FF942262AA9Q38673408-248F5844-30B1-4315-962D-E8BEAC25BD97Q38795457-1DC0FC9F-75FC-43A5-A290-C203CDE53795Q38890573-12DF0CD7-372E-46D6-B568-D0A5FDE59E24Q39201203-3A83EE5D-3948-468B-86D7-1852AD1A4D0EQ39422277-83A382BD-933C-4A5B-B55C-AB04A2BB3963Q40582623-FF2FFB39-5FCC-460A-A126-57ED4E0B7621
P2860
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
description
1996 թուականին հրատարակուած գիտական յօդուած
@hyw
1996 թվականին հրատարակված գիտական հոդված
@hy
artikull shkencor
@sq
im Januar 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 1996)
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в 1996
@uk
مقالة علمية (نشرت عام 1996)
@ar
name
Striatal glucose metabolism an ...... ents with Huntington's disease
@ast
Striatal glucose metabolism an ...... ents with Huntington's disease
@en
type
label
Striatal glucose metabolism an ...... ents with Huntington's disease
@ast
Striatal glucose metabolism an ...... ents with Huntington's disease
@en
prefLabel
Striatal glucose metabolism an ...... ents with Huntington's disease
@ast
Striatal glucose metabolism an ...... ents with Huntington's disease
@en
P2093
P921
P356
P1433
P1476
Striatal glucose metabolism an ...... ents with Huntington's disease
@en
P2093
A. Antonini
J. G. de Yébenez
K. L. Leenders
M. Weigell-Weber
P. Boesiger
P. Vontobel
R. P. Maguire
R. Sanchez-Pernaute
P304
P356
10.1093/BRAIN/119.6.2085
P407
P577
1996-01-01T00:00:00Z